Comparing three chemotherapy regimens for newly diagnosed blood cancer
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed acute myeloid leukemia (AML), confirmed by blood/bone marrow tests
- Your AML is classified as intermediate-risk or high-risk based on genetic testing
- You are between 15 and 65 years old
- Your liver and kidneys function well enough (measured by blood tests)
- Your heart is healthy with normal pumping strength
- You are physically able to tolerate intensive chemotherapy (good overall health)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests three different chemotherapy regimens (LDA, LHAA, and DA) in adults aged 18–65 with newly diagnosed acute myeloid leukemia (AML, a blood cancer). The goal is to find which approach works best and is safest for patients fit enough for intensive treatment.
This trial tests a new combination of drugs for people with acute myeloid leukemia (AML) whose cancer did not respond to or stopped responding to the usual first-line treatment. The goal is to see if this new approach can help where the previous one didn't.
This trial tests a combination of three drugs—homoharringtonine, lisaftoclax, and azacitidine—for people with acute myeloid leukemia (AML) whose cancer did not respond to or has returned after prior treatment with venetoclax. The goal is to see if this new combination can help control the leukemia when current options have failed.
; Researchers Purpose to see if anexperic compound gs the answerlies upstream and ... Let's start again.ghi briscola estratale, Steven I don't)();Interface customData = null;console.error(
This trial compares two different combinations of chemotherapy drugs for adults newly diagnosed with acute myeloid leukemia (AML). One combination uses newer targeted drugs, while the other is a standard treatment. The goal is to see which approach works better.
This trial compares two different strengths of a chemotherapy regimen that includes venetoclax (a targeted pill) for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find which dose works as well or better with fewer side effects, and it may offer a more personalized treatment option for those who can tolerate intensive therapy.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.